Anatara Lifesciences (ASX: ANR), a company focused on developing evidence-based products for unmet needs in human health, particularly those involving the gastrointestinal tract, has announced the grant of a Japanese patent for its GaRP product. The patent, titled “Gastrointestinal Health Composition,” was granted by the Japan Patent Office and is valid for 20 years from October 9, 2020. This follows similar patent grants in Hong Kong, Australia, and the EU, further strengthening the commercial potential of Anatara’s intellectual property.
The company’s Anti-Obesity Project is also progressing on schedule. Pre-clinical studies at the University of Newcastle have moved into the treatment challenge phase after preparing diet-induced obese mice. These initial studies are expected to take approximately six months to complete, with the aim of developing an oral medication to assist with weight reduction and maintenance. Anatara has allocated over $350,000 to these proof-of-concept studies.
In addition to these developments, Anatara is actively assessing other opportunities to expand its portfolio. Commercialisation discussions for the GaRP product are ongoing following positive results from the GaRP-IBS trial. The company also confirmed that its R&D Tax Incentive application has been registered for the 2024-2025 income period by AusIndustry. This registration number will be included in the company’s FY25 income tax return.
